For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Patient happy to accept the small benefits of additional ezetimibe post-ACS
+Print Archive
Practice
Patient happy to accept the small benefits of additional ezetimibe post-ACS
Wednesday 8 May 2019, 04:00 AM

A second stent placement after a myocardial infarction requires this patient to consider more aggressive lipid management. Cardiologist Chris Ellis looks at the evidence for the non-statin drug ezetimibe
A 62-year-old businessman comes in for review four months after a hospital discharge. He had been admitted with an anterior-lateral non-ST elevation m
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.